A Randomized Two-Period Crossover, Clinical Bioequivalence Study Comparing the Pharmacokinetics of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation Versus Taxol in Patients With Advanced Cancer.

Trial Profile

A Randomized Two-Period Crossover, Clinical Bioequivalence Study Comparing the Pharmacokinetics of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation Versus Taxol in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2013

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors INSYS Therapeutics, Inc; NeoPharm Inc
  • Most Recent Events

    • 30 Jun 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 25 Jul 2006 Status change
    • 18 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top